FDA Says Breast Cancer Treatment Avastin Needs Further Study
Breast cancer treatment drug Avastin does not appear to extend overall survival of breast-cancer patients and FDA will ask outside medical panel if Genentech's Avastin should be approved for breast cancer treatment.
According to the Wall Street Journal FDA questioned the capacity of Avastin to treat breast cancer and "didn't appear to extend overall survival of breast-cancer patients and will ask an outside panel of medical experts whether the drug should be approved as a breast-cancer treatment."
FDA says patients on Avastin and chemotherapy had slower cancer progression, but did not survive longer overall than patients using chemotherapy alone.
Genentech, who already has Avastin approved for part treatment for certain cancers, wants Avastin to receive FDA approval for breast-cancer treatment in combination with the chemotherapy drug paclitaxel in women with advanced breast cancer who previously haven't received chemotherapy.
FDA, in a document posted in its site, says while Avastin in an earlier study, involving about 7000 patients,